このエントリーをはてなブックマークに追加
ID 54508
JaLCDOI
フルテキストURL
Thumnail 70_4_299.pdf 1.82 MB
著者
Wada, Koichiro Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Uehara, Shinya Department of Urology, Kawasaki Hospital, Kawasaki Medical School
Ishii, Ayano Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Sadahira, Takuya Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Yamamoto, Masumi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Mitsuhata, Ritsuko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Takamoto , Atsushi Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Araki, Motoo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kobayashi, Yasuyuki Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Masami Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Watanabe, Toyohiko Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Hotta, Katsuyuki Center for innovative Clinical Medicine, Okayama University Hospital
Nasu, Yasutomo Department of Urology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
抄録
Urinary tract infections (UTIs) are the most common bacterial infections in women, and many patients experience frequent recurrence. The aim of this report is to introduce an on-going prospective phase II clinical trial performed to evaluate the preventive effectiveness of Lactobacillus vaginal suppositories for prevention of recurrent cystitis. Patients enrolled in this study are administered vaginal suppositories containing the GAI 98322 strain of Lactobacillus crispatus every 2 days or 3 times a week for one year. The primary endpoint is recurrence of cystitis and the secondary endpoints are adverse events. Recruitment began in December 2013 and target sample size is 20 participants.
キーワード
probiotics
lactobacilli
Lactobacillus crispatus
urinary tract infection
vaginal suppository
Amo Type
Clinical Study Protocols
発行日
2016-08
出版物タイトル
Acta Medica Okayama
70巻
4号
出版者
Okayama University Medical School
開始ページ
299
終了ページ
302
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
著作権者
CopyrightⒸ 2016 by Okayama University Medical School
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Sience KeyUT